Search - tctmd.com

Displaying 81 - 100 of 13264

Sort: Relevancy | Date

News Conference News TCT 2025

STRIVE: Low-Dose Alteplase Ineffective in STEMI Patients With Large Thrombus

Michael O'Riordan

October 28, 2025

Presentation TCT 2025

TCT 1957: Improved Outcomes for In-Stent Restenosis PCI With Use of Sirolimus Eluting Ultra-thin Stent Platform

Presenter: Jared Romeo

October 28, 2025

Presentation TCT 2025

TCT 892: A prospective, open-labelled, multicentre, observational registry of ISAR SUMMIT in CAD patients undergoing PCI in real world Indian population.

Presenter: Sameer I. Dani

October 28, 2025

Presentation TCT 2025

TCT 891: Safety and clinical performance of the Yukon Choice PC, Yukon Chrome PC & Yukon Choice Flex Sirolimus Eluting Bioabsorbable Polymer Stents Systems in Routine Clinical Practice: e-Yukon Global Registry.

Presenter: Bimmer E. Claessen

October 28, 2025

Presentation TCT 2025

TCT 889: A Multicenter Observational Study in France Assessing Sirolimus-Eluting Biodegradable Polymer Stent for CAD Patients Undergoing PCI in Routine Clinical Practice

Presenter: Adnan Kastrati

October 28, 2025

Presentation TCT 2025

TCT 888: DYNAMX Bioadaptor Implantation for Treatment of Complex Coronary Artery Disease – Final Results from The DYNAMITE Study

Presenter: Pier Pasquale Leone

October 28, 2025

Presentation TCT 2025

TCT 524: DCB-based versus DES-only Strategy for De Novo CAD across CHIP risk categories

Presenter: Dong Oh Kang

October 28, 2025

Presentation TCT 2025

Breakthrough Device Designation: Current Insights

Presenter: Todd J. Brinton

October 28, 2025

Presentation TCT 2025

TCT 1023: Comparative Effectiveness of DES, DCB, and BMS for the Treatment of In-Stent Restenosis in Carotid Artery Stents: A Systematic Review and Meta-Analysis

Presenter: Mehmet Cilingiroglu

October 28, 2025

Presentation TCT 2025

TCT 169: Patent Pending Ultra-Thin and Ultra-High-Pressure Balloon for Calcified Lesions (>100 atm) Using Specially Designed Carbon Fibers

Presenter: Mohammad Reza Movahed

October 28, 2025

Presentation TCT 2025

TCT 563: Comparative Outcomes of Mavacamten with AV Nodal Blockers vs. AV Nodal Blockers Alone in Patients with Hypertrophic Obstructive Cardiomyopathy: A Retrospective Cohort Study

Presenter: Aditya Desai

October 28, 2025

Presentation TCT 2025

Stent Failure Through the Ages: BMS, First-Generation DES, and Beyond

Presenter: Gary S. Mintz

October 28, 2025

Presentation TCT 2025

TCT 108: Intracoronary Imaging Values As Alternative Approach to Evaluate Significant Ischemia at Proximal Left Descending Artery

Presenter: Satoshi Terashima

October 28, 2025

Presentation TCT 2025

Should Sham Control vs Open Trial Design Make a Difference for Device Regulators and Guideline Makers?

Presenter: Gregg W. Stone

October 28, 2025

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

L.A. McKeown

October 27, 2025

News Conference News TCT 2025

PREVUE-VALVE Charts the Prevalence of Valve Disease in the United States

Caitlin E. Cox

October 27, 2025

Presentation TCT 2025

The SmartWave Lithotripsy System for Valvular Heart Disease Treatment: Technology Description and Early Clinical Results

Presenter: Kent Chak-yu So

October 27, 2025

Presentation TCT 2025

The DragonFly T-TEER for Tricuspid Regurgitation: Technology Description and Clinical Results (Case in a Box)

Presenter: Jian'an Wang

October 27, 2025

Presentation TCT 2025

TCT 945: The TASMAN Study: Third (3G) Alongside Second (2G) Generation Drug Eluting Stent (DES) and overall MACCE At Nepean: Insights from a large west of Sydney Tertiary centre during the Transition from 2G to 3G DES.

Presenter: Robert T. Gerber

October 27, 2025

Presentation TCT 2025

TCT 288: The Diabetes Effect: Mortality Risk Persists in Cardiogenic Shock STEMI Despite Contemporary PCI

Presenter: Miles Chapman

October 27, 2025

Advertisement

STRIVE: Low-Dose Alteplase Ineffective in STEMI Patients With Large Thrombus

TCT 1957: Improved Outcomes for In-Stent Restenosis PCI With Use of Sirolimus Eluting Ultra-thin Stent Platform

TCT 892: A prospective, open-labelled, multicentre, observational registry of ISAR SUMMIT in CAD patients undergoing PCI in real world Indian population.

TCT 891: Safety and clinical performance of the Yukon Choice PC, Yukon Chrome PC & Yukon Choice Flex Sirolimus Eluting Bioabsorbable Polymer Stents Systems in Routine Clinical Practice: e-Yukon Global Registry.

TCT 889: A Multicenter Observational Study in France Assessing Sirolimus-Eluting Biodegradable Polymer Stent for CAD Patients Undergoing PCI in Routine Clinical Practice

TCT 888: DYNAMX Bioadaptor Implantation for Treatment of Complex Coronary Artery Disease – Final Results from The DYNAMITE Study

TCT 524: DCB-based versus DES-only Strategy for De Novo CAD across CHIP risk categories

Breakthrough Device Designation: Current Insights

TCT 1023: Comparative Effectiveness of DES, DCB, and BMS for the Treatment of In-Stent Restenosis in Carotid Artery Stents: A Systematic Review and Meta-Analysis

TCT 169: Patent Pending Ultra-Thin and Ultra-High-Pressure Balloon for Calcified Lesions (>100 atm) Using Specially Designed Carbon Fibers

TCT 563: Comparative Outcomes of Mavacamten with AV Nodal Blockers vs. AV Nodal Blockers Alone in Patients with Hypertrophic Obstructive Cardiomyopathy: A Retrospective Cohort Study

Stent Failure Through the Ages: BMS, First-Generation DES, and Beyond

TCT 108: Intracoronary Imaging Values As Alternative Approach to Evaluate Significant Ischemia at Proximal Left Descending Artery

Should Sham Control vs Open Trial Design Make a Difference for Device Regulators and Guideline Makers?

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

PREVUE-VALVE Charts the Prevalence of Valve Disease in the United States

The SmartWave Lithotripsy System for Valvular Heart Disease Treatment: Technology Description and Early Clinical Results

The DragonFly T-TEER for Tricuspid Regurgitation: Technology Description and Clinical Results (Case in a Box)

TCT 945: The TASMAN Study: Third (3G) Alongside Second (2G) Generation Drug Eluting Stent (DES) and overall MACCE At Nepean: Insights from a large west of Sydney Tertiary centre during the Transition from 2G to 3G DES.

TCT 288: The Diabetes Effect: Mortality Risk Persists in Cardiogenic Shock STEMI Despite Contemporary PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content